Mr. Cobbs is a Managing Director of Signet Healthcare Partners and has more than twenty five years experience in the health sciences and biotechnology industries.

He presently serves on the board of directors of Cedarburg Pharmaceuticals, Bioject Medical Technologies (BJCT) and the Texas Life Science Center for evaluation and commercialization of early stage life science companies in Texas through the $300 million Emerging Technology Fund. He is a board observer to OptiScan Biomedical Corporation and Functional Genetics, Inc.

Mr. Cobbs previously served as the Assistant Director of Technology Development at the University of Texas – M.D. Anderson Cancer Center, in the Houston Medical Center. During his tenure at M.D. Anderson, he helped form two molecular therapy companies: Introgen Therapeutics (Nasdaq: INGN), a pioneer in gene-based therapies for a variety of cancers based in Austin, Texas and Rgene Therapeutics, which was sold to Targeted Genetics, Inc. (Nasdaq: TGEN).

Mr. Cobbs was also Chairman and Chief Executive Officer of Quantitative Diagnostic Laboratories, a cancer diagnostic and image analysis company based in Chicago, Illinois (sold to Ventana Medical Systems, now Roche Diagnostics).

Mr. Cobbs received his Masters of Business Administration from the University of Houston.

Mrs. Erony joined Signet Healthcare Partners in 2006 and has more than 20 years experience as a principal in investing activities, investment banking and business development.

She has served as a director of Dow Pharmaceutical Sciences, Control Delivery Systems (acquired by Psivida) and Orbis and as a strategic advisor to Alcon Labs.

Previously, Ms. Erony was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies. Prior to her 15 year career at Citigroup, Ms. Erony served as an economist to a number of international development agencies and multilateral organizations.

Ms. Erony received her graduate degree from the London School of Economics and a Bachelors of Science from Case Western Reserve University.

Mr. Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A., and also serves on the Board of Directors of Cedarburg Pharmaceuticals Inc., Cydex Inc., Indevus Pharmaceuticals, Inc., Spepharm BV and Paladin Laboratories.

Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale’s investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co.

Mr. Gale received his Masters of Business Administration from the University of Chicago.

Mr. Hansen has been a Managing Director of Signet Healthcare Partners, since 2001. Mr. Hansen has over 20 years of private equity investment experience.

He was Chairman and interim CEO of Questcor Pharmaceuticals and currently serves as a Director of BioPro Pharmaceutical, Cedarburg Pharmaceuticals, LearnWright, and Malladi Drugs and Pharmaceuticals.

Mr. Hansen’s previous experience includes serving as a principal of Darby Overseas Investments Ltd., a private equity firm with a focus on emerging markets and as Director of Corporate Finance at the U.S. Treasury Department.

Early in his career, Mr. Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions and an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer.

Mr. Hansen has a B.A. from Princeton University and a Masters of Business Administration from the Wharton School, University of Pennsylvania.

Mr. Zeiger is an Adjunct Partner with Signet Healthcare Partners.
He has more than 25 years experience in many aspects of management in the pharmaceutical industry, both branded and generic.

Mr. Zeiger is currently a Director of BioPro, Cedarburg Pharmaceuticals and the Larry King Cardiac Foundation and is a member of the supervisory board for Pliva Pharmaceuticals, a $2 billion pharmaceutical company recently acquired by Barr Laboratories.

Prior to joining Signet Healthcare Partners, Mr. Zeiger was a Senior Vice President at Barr Laboratories, Inc. Prior to joining Barr, Mr. Zeiger was Executive Vice President and General Counsel at Rugby Laboratories (a privately held generic drug company) until its acquisition by Marion Merrill Dow, Inc. in 1993. He continued as a Vice President for Marion and its successor Company, Hoechst Marion Roussel, Inc.

Mr. Zeiger was honored by Generic Pharmaceutical Industry Association at its March 2004 Annual Meeting as a generic industry founder. Prior to joining pharmaceutical manufacturing companies, Mr. Zeiger served as Vice President General Counsel for Jack Eckerd Corporation and Senior Vice President for Revco D.S. Inc. both major drug store retailers.

Mr. Zeiger is an attorney, admitted to practice in the State of New York.

He received his LLB and JD from St.John’s University School of Law, where he served as Publications Editor of the Law Review.